TheBioTechReview

Therapeutics

Exploring the latest in Therapeutics.

Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
Therapeutics

Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

At AAIC 2026, Biogen presented promising anti-tau data for diranersen, while psychedelics advance with Compass positive results and FDA guidance. Meanwhile, ATTR-CM faces a setback as AstraZeneca and Ionis' Wainua fails a Phase 3 trial.

Global Medicine Use Trends to 2030: China's Rise, Specialty Therapies, and the Shift from Volume to Value
Therapeutics

Global Medicine Use Trends to 2030: China's Rise, Specialty Therapies, and the Shift from Volume to Value

The Paradox of Plenty: Why Life Sciences Must Reconfigure Its Innovation Model for 2025
Therapeutics

The Paradox of Plenty: Why Life Sciences Must Reconfigure Its Innovation Model for 2025

When Data Goes Dark: How Automated Content Filters Disrupt Healthcare Market Intelligence
Therapeutics

When Data Goes Dark: How Automated Content Filters Disrupt Healthcare Market Intelligence

Global Pharmaceutical Market 2025: Specialty Drugs, GLP-1 Revolution, and the Biologics Shift – A Deep Analysis
Therapeutics

Global Pharmaceutical Market 2025: Specialty Drugs, GLP-1 Revolution, and the Biologics Shift – A Deep Analysis

Drug Design, Development and Therapy Volume 6 (2012): What the Archive Reveals About Drug Development Trends, Clinical Translation, and Open Access Publishing
Therapeutics

Drug Design, Development and Therapy Volume 6 (2012): What the Archive Reveals About Drug Development Trends, Clinical Translation, and Open Access Publishing